STOCK TITAN

683 Capital reports 5.23% stake in Gossamer Bio (GOSS)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

683 Capital Management, LLC and related reporting persons reported beneficial ownership in Gossamer Bio. As of March 2, 2026, the reporting persons beneficially owned 8,000,000 shares of common stock plus warrants exercisable for 4,331,304 shares, totaling 12,331,304 shares, or 5.23% of common stock on the basis described in the filing. The filing states the 4,331,304 warrants are currently exercisable and that voting and dispositive power over these securities is shared among the reporting persons.

The percentage uses an outstanding share base of 231,456,247 common shares as of October 31, 2025, plus the 4,331,304 exercisable-warrant shares, per the disclosure.

Positive

  • None.

Negative

  • None.

Insights

Large holder reports a 5.23% stake including exercisable warrants.

The filing discloses beneficial ownership of 8,000,000 common shares plus warrants exercisable for 4,331,304 shares, totaling 12,331,304 shares as of March 2, 2026. The percentage is calculated using 231,456,247 shares outstanding as of October 31, 2025 plus the exercisable warrants, per the filing.

Holder control is described as shared voting and dispositive power. The filing is a standard beneficial-ownership disclosure and does not itself change holdings; subsequent Form 4s would report transactions if shares or warrants are traded or exercised.

Joint filing and manager attribution clarify reporting relationships.

The Schedule 13G lists 683 Capital Partners, LP as direct beneficial owner and 683 Capital Management, LLC and Ari Zweiman as attributable via management roles; a Joint Filing Agreement is attached and signed on March 2, 2026. The filing ties beneficial ownership to currently exercisable warrants of 4,331,304 shares.

Voting and dispositive power are reported as shared on the cover pages. This is a compliance disclosure under securities rules; it documents positions and attributions rather than announcing a transaction.






02/23/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



683 Capital Management, LLC
Signature:Ari Zweiman
Name/Title:Managing Member
Date:03/02/2026
683 Capital Partners, LP
Signature:Ari Zweiman
Name/Title:Authorized Person
Date:03/02/2026
Ari Zweiman
Signature:Ari Zweiman
Name/Title:Self
Date:03/02/2026
Exhibit Information

JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of Common Stock, par value $0.0001 per share, of Gossamer Bio, Inc. dated as of March 2, 2026 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended. Dated: March 2, 2026 683 CAPITAL MANAGEMENT, LLC By: /s/ Ari Zweiman Ari Zweiman, Managing Member 683 CAPITAL PARTNERS, LP By: /s/ Ari Zweiman Ari Zweiman, Authorized Person /s/ Ari Zweiman Ari Zweiman

FAQ

What stake does 683 Capital report in GOSS?

The reporting persons state beneficial ownership of 12,331,304 shares including exercisable warrants. This equals 5.23% of common stock on the stated basis in the filing.

How is the 12,331,304 total constructed in the filing?

The total combines 8,000,000 directly beneficial shares and warrants exercisable for 4,331,304 shares; the filing describes the warrants as currently exercisable as of March 2, 2026.

What share count did the filing use to calculate the percentage?

The percentage is based on 231,456,247 shares outstanding as of October 31, 2025 from the issuer's Form 10-Q, plus the 4,331,304 exercisable-warrant shares, per the filing.

Who is reported as having voting and dispositive power?

The cover pages indicate shared voting and shared dispositive power over the 12,331,304 shares; the filing attributes control among 683 Capital Partners, 683 Capital Management, LLC, and Ari Zweiman.

Does the filing show any transactions or changes in holdings?

This Schedule 13G is a beneficial-ownership disclosure dated March 2, 2026 and describes positions and attribution; it does not report open-market buy/sell transactions within this excerpt.
Gossamer Bio

NASDAQ:GOSS

GOSS Rankings

GOSS Latest News

GOSS Latest SEC Filings

GOSS Stock Data

120.77M
218.57M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO